Bone marrow mesenchymal stem cells (BMSCs) exhibit an age-dependent reduction in osteogenesis that is accompanied by an increased propensity toward adipocyte differentiation. This switch increases adipocyte numbers and decreases the number of osteoblasts, contributing to age-related bone loss. Here, we found that the level of microRNA-188 (miR-188) is markedly higher in BMSCs from aged compared with young mice and humans. Compared with control mice, animals lacking miR-188 showed a substantial reduction of age-associated bone loss and fat accumulation in bone marrow.
Introduction
Bone marrow mesenchymal stem cells (BMSCs) have the potential to differentiate into various cell types, including adipocytes, chondrocytes, and osteoblasts (1, 2) . Age-related osteoporosis is characterized by reduced bone formation and increased marrow fat accumulation (3) (4) (5) (6) . This age-related reduction in osteoblast activity is partly caused by the fact that BMSCs from elderly subjects have reduced capacity to differentiate into osteoblasts and increased capacity to differentiate into adipocytes (3, 4) . However, the molecular mechanisms behind the shift from osteoblast to adipocyte differentiation in BMSCs remain elusive.
MicroRNAs (miRNAs) are a class of small (~22 nucleotides), single-stranded noncoding RNAs found in diverse organisms, which downregulate the expression of target genes by either mRNA degradation or translational inhibition (6, 7) . Recently, several miRNAs were found to be involved in either osteogenesis or adipogenesis (8) (9) (10) (11) (12) . However, most of these miRNAs have only been investigated in vitro, and their functional roles in the pathophysiological mechanisms responsible for age-related bone loss and accumulation of fat in bone marrow remain to be established. The roles of miRNAs in the age-related switch between osteoblast and adipocyte differentiation of BMSCs in bone marrow are also unclear.
Here, we identified a novel, highly expressed miRNA, miR-188, from the BMSCs of aged mice and human subjects. Our study demonstrated that miR-188 regulates BMSCs' bifurcation into osteoblasts and adipocytes during aging. Knockout of Mir188 in mice reduced age-associated trabecular and cortical bone loss and marrow fat accumulation. Notably, intra-bone marrow injection of BMSC-targeting aptamer-antagomiR-188 stimulated trabecular and cortical-endosteal bone formation and decreased bone marrow fat accumulation in aged mice. Thus, our study provides a new mechanism and a novel therapeutic target for age-related bone loss.
Results
Aging induces miR-188 expression in BMSCs. Histological and immunohistochemical analyses of femora revealed increased number and area of adipocytes characterized by fat vacuoles in bone marrow and decreased number of osteocalcin-positive osteoblasts on the trabecular and endosteal bone surfaces in aged mice (18 months old) compared with young mice (3 months old) ( Figure 1 , A-D, and Supplemental Figure 1 ; supplemental material available online with this article; doi:10.1172/JCI77716DS1). The increased bone marrow fat accumulation and decreased osteoblasts implied a switch from osteogenic differentiation to adipogenic differentiation of BMSCs. To determine the mechanism of the age-related differentiation switch of BMSCs, Sca-1 + CD29 + CD45 -CD11bmesenchymal stem cells were sorted by FACS from bone marrow cells (13) of young and aged mice to identify dysregulated miRNAs by performing miRNA microarray analysis ( Figure 1E ). Among them, miR-188 showed the largest difference in expression between the 2 groups, being expressed approximately 30 times more highly in aged mice compared with young mice. The raw data of the microarray have been uploaded to GEO with the series record GSE57127 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE57127).
Bone marrow mesenchymal stem cells (BMSCs) exhibit an age-dependent reduction in osteogenesis that is accompanied by an increased propensity toward adipocyte differentiation. This switch increases adipocyte numbers and decreases the number of osteoblasts, contributing to age-related bone loss. Here, we found that the level of microRNA-188 (miR-188) is markedly higher in BMSCs from aged compared with young mice and humans. Compared with control mice, animals lacking miR-188 showed a substantial reduction of age-associated bone loss and fat accumulation in bone marrow. Conversely, mice with transgenic overexpression of miR-188 in osterix + osteoprogenitors had greater age-associated bone loss and fat accumulation in bone marrow relative to WT mice. Moreover, using an aptamer delivery system, we found that BMSC-specific overexpression of miR-188 in mice reduced bone formation and increased bone marrow fat accumulation. We identified histone deacetylase 9 (HDAC9) and RPTOR-independent companion of MTOR complex 2 (RICTOR) as the direct targets of miR-188. Notably, BMSC-specific inhibition of miR-188 by intra-bone marrow injection of aptamer-antagomiR-188 increased bone formation and decreased bone marrow fat accumulation in aged mice. Together, our results indicate that miR-188 is a key regulator of the age-related switch between osteogenesis and adipogenesis of BMSCs and may represent a potential therapeutic target for age-related bone loss.
MicroRNA-188 regulates age-related switch between osteoblast and adipocyte differentiation changed in Mir188 -/mice relative to their WT littermates (Supplemental Figure 3B ). In vitro, BMSCs from Mir188 -/mice exhibited increased osteogenesis and decreased adipogenesis ( Figure 3J ). However, culture of bone marrow monocytes/macrophages showed that osteoclast formation was not affected (Supplemental Figure 3C ). Taken together, the results suggest that Mir188 -/mice have reduced age-associated bone loss and marrow fat accumulation.
Transgenic expression of miR-188 in osterix + osteoprogenitors leads to an accelerated bone marrow fat accumulation and bone loss.
We then constructed transgenic mice overexpressing miR-188 in osterix + osteoprogenitors to investigate whether overexpression of miR-188 in vivo would lead to bone loss and marrow fat accumulation. qRT-PCR revealed significantly higher levels of miR-188 expression in both line 1 and line 2 as compared with that in WT controls (Supplemental Figure 4A ). Both line 1 and line 2 (6 months of age) had lower trabecular bone volume of femur and vertebra relative to WT controls ( Figure 4 , A-E and I, and Supplemental Figure 4B ). We chose the line 1 mice with higher miR88 expression (referred to as "transgenic mice" hereafter) for detailed analysis.
The cortical bone thickness was higher and the endosteal perimeter was lower in the femora of aged Mir188 -/mice compared with their WT littermates (Figure 2 , F-H). The vertebral bone volume was also higher in aged Mir188 -/mice compared with their WT littermates ( Figure 2 , I and J). Accordingly, values of the tibia maximum load and stiffness, which represent bone strength, were higher in the aged Mir188 -/mice than in their WT littermates ( Figure 2 , K and L). Calcein double labeling confirmed that aged Mir188 -/mice had significantly higher trabecular and endosteal bone formation rates (BFRs) compared with their WT littermates ( Figure 3 , A-D). However, no significant differences were observed between the young (3 months old) Mir188 -/mice and their WT littermates ( Figure 2 and Figure 3 , A-I).
Aged, but not young, Mir188 -/mice had significantly decreased number and area of adipocytes in the bone marrow (Figure 3 Figure 5B ). Thus, these data confirm that overexpressing miR-188 in osterix + osteoprogenitors of transgenic mice leads to bone loss and an accelerated formation of fatty marrow.
Mice with BMSC-specific overexpression of miR-188 using aptamer delivery system present reduced bone formation and increased bone marrow fat. To investigate the effects of miR-188 overexpression in BMSCs of mice, agomiR-188 was injected into the bone marrow with a BMSC-targeting aptamer, which can specifically bind to BMSCs (16) (17) (18) . We tested the ability of the aptamer to bind to mouse BMSCs, monocytes/macrophages, and preosteoclasts.
The trabecular bone volume, number, and cortical bone thickness were lower, and the trabecular separation and endosteal perimeter were higher, in the femora of 6-month-old and 12-month-old transgenic mice relative to WT controls ( Figure 4 , A-H). The vertebral bone volume was also lower in miR-188 transgenic mice relative to WT controls ( Figure 4I ). In addition, bone strength was lower in the miR-188 transgenic mice compared with WT controls (Figure 4 Figure 6D ). These results reveal that mice with BMSC-specific overexpression of miR-188 have reduced bone formation and increased bone marrow fat.
MiR-188 promotes adipogenic differentiation of BMSCs. The qRT-PCR data showed that miR-188 expression increased gradually during adipogenesis of BMSCs ( Figure 6A ). To investigate the role of miR-188 during adipogenesis, BMSCs were transfected with the agomiR-188 or antagomiR-188 to overexpress or silence miR-188 ( Figure 6B ). The BMSCs were then cultured in adipogenesis induction medium. Overexpression of miR-188 facilitated lipid droplet formation in BMSCs induced by adipogenesis FACS analysis showed that binding shift was observed only in BMSCs, not in monocytes/macrophages or preosteoclasts, demonstrating that the selected aptamer had high specificity for BMSCs (Supplemental Figure 6A) .
The qRT-PCR results also confirmed that intra-bone marrow injection of aptamer-agomiR-188 caused a significant increase in the level of miR-188 expression in BMSCs, but not in monocytes/ macrophages or preosteoclasts ( Figure 5A Figure 6G ). The raw data of the microarray have been uploaded to GEO with the series record GSE63725 (http://www.ncbi.nlm.nih. gov/geo/query/acc.cgi?acc=GSE63725). All of these results suggest that miR-188 promotes adipogenic differentiation of BMSCs. MiR-188 inhibits osteoblastic differentiation of BMSCs. The expression of miR-188 decreased gradually during osteogenesis, as assessed by qRT-PCR ( Figure 7A ). To investigate the role of miR-188 during osteoblastic differentiation, BMSCs were transfected with agomiR-188 or antagomiR-188 to overexpress or silence miR-188 and then cultured in osteogenesis induction medium. Overexpression of miR-188 inhibited, while silencing of miR-188 promoted, osteogenic differentiation of BMSCs measured by Alizarin Red staining (Figure 7 , B and C).
Consistently, osteoblast differentiation markers, alkaline phosphatase (ALP) activity and osteocalcin secretion, were lower in agomiR-188-transfected cells compared with control cells (Figure 7 , D and E). Moreover, the mRNA level of the late-stage second osteoblast transcription factor osterix, but not the first osteoblast transcription factor Runx2, was inhibited by agomiR-188 ( Figure 7 , F and G). Conversely, antagomiR-188 transfection promoted osteogenic differentiation and increased osterix expression (Figure 7 , B-G). Moreover, gene microarray analysis further confirmed that Alpl (ALP), Col1a (collagen type I α), Sp7 (osterix), and other osteoblast differentiation markers were higher in osteoblastic induction medium-induced BMSCs of Mir188 -/mice as compared with their WT littermates ( Figure 7H ). The raw data of the microarray have been uploaded to GEO with the series record GSE63725 (http://www.ncbi.nlm.nih.gov/geo/query/acc. cgi?acc=GSE63725). All of these results suggest that miR-188 inhibits osteogenic differentiation of BMSCs. MiR-188 directly targets HDAC9 and Rictor. MiRNAs regulate the expression of mRNAs by binding to the 3′-untranslated regions (3′-UTRs) or amino acid coding sequences of target genes. We used miRanda (19) , PicTar (20) , and TargetScan (21) to predict the targets of miR-188. Among the predicted genes, we chose 6 for further analysis-histone deacetylase 9 (Hdac9), RPTORindependent companion of MTOR complex 2 (Rictor), phosphatase and tensin homolog (Pten), zinc finger protein 281 (Znf281), GLIS family zinc finger 3 (Glis3), and ephrin B2 (Efnb2)-which had been reported to participate in bone metabolism (22) (23) (24) (25) (26) (27) (28) . Overexpression or inhibition of miR-188 changed endogenous levels of HDAC9 and RICTOR protein, but not the others ( Figure  8A ). However, no changes of the mRNA levels of Hdac9 and Rictor were noted (Supplemental Figure 7) . To investigate whether miR-188 directly targets HDAC9 and RICTOR, luciferase reporter constructs containing the predicted miRNA-binding site of HDAC9 and RICTOR (WT-pGL3-HDAC9, WT1-pGL3-RICTOR, or WT2-pGL3-RICTOR) were generated (Supplemental Table 1 ). We transfected WT-pGL3-HDAC9, WT1-pGL3-RICTOR, or WT2-pGL3-RICTOR with agomiR-188 or agomiR-NC into BMSCs and measured the effects of miR-188 on luciferase translation by the level of luciferase enzyme activity. Overexpression of miR-188 suppressed the luciferase activity of the Hdac9 or Rictor 3′-UTR reporter genes (Figure 8 , C-E). Mutation of 2 nucleotides within the sequences of the putative target site in the 3′-UTR of Hdac9 or Rictor (MUT-pGL3-HDAC9, MUT1-pGL3-RICTOR, or MUT2-pGL3-RICTOR) abolished this repression, confirming the specificity of miR-188's action (Figure 8 , C-E).
We also detected the protein of HDAC9 or RICTOR in BMSCs of aged (18 months) and young (3 months) WT and Mir188 -/mice. HDAC9 and RICTOR protein levels were lower in 18-month-old WT mice compared with 3-month-old WT mice, while in Mir188 -/- Figure 8E) . These results demonstrate that HDAC9 and RICTOR are the targets of miR-188 in both mouse and human.
Injection of antagomiR-188 into bone marrow stimulates bone formation and decreases bone marrow fat in aged mice. To investigate the therapeutic effects of BMSC-specific inhibition of miR-188 on age-related osteoporosis, aptamer-antagomiR-188 was injected into the femoral bone marrow cavity of 15-month-old mice twice per month for 3 months. Intra-bone marrow injection of BMSCtargeting aptamer-antagomiR-188 significantly decreased the levels of miR-188 in BMSCs ( Figure 9A ). Aptamer-antagomiR-188 increased the trabecular bone volume, number, and cortical bone thickness, and decreased trabecular separation and the endosteal perimeter (Figure 9 , B-I). Furthermore, bone strength increased in those mice that received aptamer-antagomiR-188 treatment (Fig-mice , HDAC9 and RICTOR protein levels were similar in young and aged mice ( Figure 8F ). However, HDAC9 and RICTOR protein levels were significantly lower in miR-188 transgenic mice compared with their WT littermates ( Figure 8F ).
Whether the miR-188 targets in HDAC9 and RICTOR are preserved in humans was also investigated. Sequence analysis revealed that binding sites for hsa-miR-188 in the 3′-UTR of human HDAC9 (position 1905-1912) and RICTOR (position 4344-4351) are conserved in mice (Supplemental Figure 8, A and B , and Supplemental Table 1 ). Luciferase reporter constructs containing the predicted miRNA-binding site of the human HDAC9 and RIC-TOR (WT-pGL3-hHDAC9 and WT-pGL3-hRictor) were generated (Supplemental Figure 8B) related switch between osteoblast and adipocyte differentiation in bone marrow remain unclear. In this study, we revealed elevated miR-188 expression in BMSCs from aged mice and human subjects. Furthermore, Mir188 -/mice showed reduced age-associated bone loss and marrow fat accumulation. Osterix + osteoprogenitorspecific miR-188 transgenic mice showed accelerated bone marrow fat accumulation and bone loss. These results reveal that miR-188 regulates the differentiation directions of BMSCs during aging and contributes to age-related bone loss. Previously, it was reported that miR-188 regulates dendritic plasticity and synaptic transmission (29) , and suppresses G1/S transition (30) . However, there is no report on the role of miR-188 in the regulation of BMSC function. In this study, we defined a new mechanism whereby miR-188 regulates the BMSC switch in bone. MiRNAs mediate post-transcriptional gene silencing by base pairing to the complementary sites in the 3′-UTR of the target mRNA (31) . We demonstrated that miR-188 directly targets Hdac9 and Rictor mRNAs. HDAC9, which is dramatically downregulated during adipogenesis, inactivates PPARγ to repress adipogenesis and promote osteogenesis of BMSCs (22, 23) . RIC-TOR, as a key component of mTORC2, which is a member of the mTOR complex implicated in resting cytoskeletal architecture, suppresses PPARγ activity and inhibits adipogenic differentia-ure 9, J and K). Notably, trabecular and endosteal BFR increased in mice treated with aptamer-antagomiR-188 ( Figure 9 , L-N). Aptamer-antagomiR-188 also decreased the number and area of adipocytes in bone marrow, and increased the number and surface of osteoblasts on trabecular and endosteal bone surfaces (Figure 9 , O-R, and Supplemental Figure 9, A and B) . However, there were no differences of number and surface of osteoclasts on the trabecular bone surface (Supplemental Figure 9B) .
These results suggest that intra-bone marrow injection of antagomiR-188 would prevent bone loss and marrow fat accumulation in aged mice.
Discussion
BMSCs tend to differentiate into adipocytes rather than osteoblasts with aging, which leads to progressive accumulation of fat and bone loss (3) (4) (5) (6) (7) . Here we demonstrated that miR-188 is involved in this shift of cell lineage commitment of BMSCs, using Mir188 knockout and overexpression transgenic mice. Furthermore, inhibiting miR-188 with a BMSC-specific delivery system reduced fat accumulation and promoted trabecular and corticalendosteal bone formation in aged mice.
Several miRNAs have been reported to regulate BMSC lineage commitment (8) (9) (10) (11) (12) . However, the roles of miRNAs in the age- With the progressive aging of the general population, agerelated bone loss becomes a growing public problem (32) . A major requirement for the treatment of age-related bone loss is to identify anabolic agents that can increase bone formation and decrease fat accumulation in bone marrow via targeting BMSCs (33) . In this study, we identified a new mechanism for developing this treatment. We used a BMSC-specific aptamer to deliver antagomiR-188 or agomiR-188 into mice BMSCs. Aptamers are single-stranded nucleic acid molecules that bind to targets via folding into a 3-dimensional structure with high affinity and selectivity (34, 35) . Cell typespecific aptamers as drug delivery vehicles have been exploited to enhance the efficacy and safety of therapeutic drugs used in cancer (36, 37) , HIV (38, 39) , and eye-related diseases (40) . Treatment with antagomiR-188 via a BMSC-specific aptamer increased bone tion of mesenchymal stem cells (24) . The present study showed that miR-188 post-transcriptionally inhibits HDAC9 and Rictor expression and upregulates PPARγ expression during adipogenic differentiation of BMSCs.
Thus, the observation that translations of Hdac9 and Rictor are inhibited by miR-188 provides a molecular link to the age-related switch between osteoblast and adipocyte differentiation. During aging, miR-188 expression is induced in BMSCs. MiR-188 suppresses the production of HDAC9 and Rictor in BMSCs, which activates the adipogenic transcription factor PPARγ. Consequently, BMSCs favor differentiation into adipocytes, resulting in an increased number of adipocytes and a decreased number of osteoblasts, causing agerelated bone loss. Thus, our study revealed a new mechanism whereby miR-188 regulates the differentiation of BMSCs during aging. All mice were maintained in the specific pathogen-free facility of the Laboratory Animal Research Center at Central South University.
BMSC isolation and culture. For mouse BMSC isolation, bone marrow cells were flushed from femora of female mice and incubated for 20 minutes at 4°C with PE-, FITC-, peridinin chlorophyll protein-, and allophycocyanin-conjugated antibodies that recognized mouse Sca-1 (108108; BioLegend), CD29 (102206; BioLegend), CD45 (103132; BioLegend), and CD11b (101226; BioLegend). For human BMSC isolation, human bone marrow cells were incubated with FITC-, allophycocyanin-, and PE-conjugated antibodies that recognized human STRO-1 (catalog 340106; BioLegend), CD45 (catalog 304012; Bio Legend), and CD146 (catalog 361008; BioLegend) at 4°C for 30 minutes. Acquisition was performed on a FACS Aria model (BD Biosciences), and the analysis was performed using FACS DIVE software version 6.1.3 (BD Biosciences).
The sorted mouse CD29 + Sca-1 + CD45 − CD11b − BMSCs and human CD146 + STRO-1 + CD45 − BMSCs were cultured for 1-2 weeks to reach 80%-85% confluence. Then, first-passage BMSCs were detached and seeded in culture flasks for enrichment of cell populations. As second-passage BMSCs reached confluence after approximately 1 week, they were subcultured. Only third-passage BMSCs were subjected to induction of adipogenic and osteogenic differentiation, and transfection of plasmids.
MiRNA microarray assay. Small RNAs were isolated from the total RNA of BMSCs from young (3 months old) and aged (18 months old) female C57BL/6 mice, and then labeled with Cy3. The Oebiotech Company performed the miRNA microarray assay. The fragmentation mixtures were hybridized to an Agilent-046065 Mouse miRNA Microarray V19.0 8×60K (Agilent). Feature Extraction software 10.7.1.1 (Agilent) analyzed the scanned images using default parameters to obtain background subtracted and spatially detrended processed signal intensities as the raw data. Raw data were normalized in a quantile algorithm with Genespring 12.0 (Agilent). Probes for which at least 100% of samples in any 1 condition out of 2 conditions had flags in "Detected" were maintained. The raw data of the microarray have been uploaded to GEO with the series record GSE57127.
Gene chip microarray assay. RNAs were isolated from WT and Mir188 -/mouse-derived BMSCs cultured with adipogenesis induction medium or osteogenesis induction medium for 48 hours. The RNAs were sent to the UCLA Clinical Microarray Core to perform the gene chip microarray assay. The fragmentation mixtures were hybridized to an Affymetrix mouse 1.0 gene ST array. Robust multiarray average was used to perform the data normalization. Principal component analysis in Partek Genomics Suite was used to perform the cluster analysis of different samples. ANOVA was used to identify the differential expression genes. The raw data of the microarray have been uploaded to GEO with the SuperSeries record GSE63725.
Histochemistry analysis. Histochemistry analysis was performed as described previously (42, 43) . Briefly, femora were harvested from mice after euthanasia, fixed in 10% formalin for 24 hours, and decalcified in 10% EDTA for 14 days, before being embedded in paraffin. Four-micrometer-thick longitudinally oriented bone sections were stained with H&E, TRAP, and toluidine blue to quantify number and surface of osteoblasts, number and surface of osteoclasts, and number and area of adipocytes, respectively.
OsteoMeasureXP Software (OsteoMetrics Inc.) performed histomorphometric measurements of 2-dimensional parameters of the formation and decreased bone marrow fat accumulation in aged mice, while treatment with agomiR-188 led to premature aging of bone in middle-aged mice, as evidenced by reduced bone formation and increased bone marrow fat. Currently, most drugs for osteoporosis that are available in the clinic inhibit bone resorption without increasing bone formation (41) . Our results indicate that inhibition of miR-188 expression in BMSCs via an aptamer might be a new strategy to treat age-related bone loss and senile osteoporosis.
In conclusion, the current findings support the view that the age-related increase in miR-188 functions as a switch to regulate BMSC differentiation. The results reveal a new mechanism of agerelated bone loss and identify a potential therapeutic target.
Methods
Construction of Mir188 -/mice using TALEN plasmids. The miR-188specific TALEN plasmids were obtained from Beijing ComWin Biotech Co. Ltd. The target TALEN sequences of the Mir188 were: left, 5′-CCCTGCTCCCTCTCTCAC-3′, and right, 5′-CAGAGAGCTCAC-CCTC-3′. TALEN plasmids were digested by NotI restriction endonuclease. The digested plasmids were transcribed to mRNA in vitro using the mMESSAGE mMACHINE T7 Kit (Life Technologies), according to the manufacturer's instructions. We purified the synthesized mRNAs using a MegaClear Kit (Life Technologies), according to the manufacturer's instruction. The mRNAs were diluted to working concentration (50 ng/μl) in injection buffer (0.25 mM EDTA, 10 mM Tris, pH 7.4) treated with diethyl pyrocarbonate (Sigma-Aldrich).
C57BL/6 mice were used as embryo donors and were superovulated. The TALEN mRNAs were injected into the cytoplasm of pronuclear-stage fertilized eggs, which were obtained from oviducts after superovulated female C57BL/6 mice were mated to C57BL/6 stud males. The injected zygotes were cultured in M2 medium (Sigma-Aldrich) at 37°C for 24 hours. Zygotes that developed into the 2-cell stage were selected to transfer into the oviducts of pseudopregnant imprinting control region (ICR) female mice.
Genomic DNA was extracted from tail tips. For genotyping of miR-188, PCR was carried out using the following primers (synthesized by Sangon Biotech): forward, 5′-TCTTGGTCCGCATGTGTGTG-3′, and reverse, 5′-AGGGAGTTCAAAGGCAGCATG-3′. To determine the accuracy of PCR, we collected the PCR products from agarose gel to use as templates for sequencing.
Generation of osterix + osteoprogenitor-specific miR-188 transgenic mice. To generate osterix + osteoprogenitor-specific miR-188 transgenic (miR-188-Tg) mice, a plasmid containing the osterix promoter to drive gene expression was constructed. First, we subcloned the mouse pre-mir-188 cDNA (synthesized by Genscript Co.) into the SalI-EcoRI site in a plasmid containing the osterix promoter, resulting in osterixpre-mir-188 vector. The plasmid (osterix-pre-miR-188) was then transfected into BMSCs using Lipofectamine 2000 (Invitrogen). Empty vector was also transfected into BMSCs as a control. qRT-PCR was used to detect the expression of miR-188. The fragments of the osterixpre-mir-188 were then purified and microinjected into C57BL/6J F 2 mouse oocytes, and the oocytes were then surgically transferred into pseudopregnant C57BL/6J dams. Two lines with high levels of miR-188 expression were selected from 5 transgenic founders and bred in C57BL/6 strain for 6 generations to obtain offspring with a defined genetic background. One line with a sevenfold overexpression of miR-188 was extensively studied. The WT mice were used as controls. jci.org Volume 125 Number 4 April 2015
to form the PEI-citrate core structure (nanocore). Then, we added 3 parts by volume of synthetic BMSC aptamers (50 nM) and agomiR-188 (1 μM) or antagomiR-188 (1 μM) to the nanocore for 5 minutes of reaction to assemble the nanocomplex. Mice received either 40 μl of an agomiR-188 nanocomplex or an antagomiR-188 nanocomplex, or a comparable volume of PBS via periosteal injection into medullary cavity of femur twice per month for 3 months.
mRNA 3′-UTR cloning and luciferase reporter assay. For functional analysis of miR-188, the segments of the mouse and human HDAC9 and Rictor 3′-UTR, including the predicted miR-188-binding site, were PCR-amplified. The PCR products were purified and inserted into the XbaI-FseI site immediately downstream of the stop codon in the pGL3 control luciferase reporter vector (Promega Corp.), resulting in mouse and human WT-pGL3-HDAC9, WT1-pGL3-RICTOR, or WT2-pGL3-RICTOR. The HDAC9 and RICTOR mutants for the miR-188 seed regions were prepared using the QuikChange Site-Directed Mutagenesis Kit (Stratagene) to get mouse and human MUT-pGL3-HDAC9, MUT1-pGL3-RICTOR, or MUT2-pGL3-RICTOR. Mouse and human BMSCs were transfected with either WT or mutant pGL3 construct, the pRL-TK renilla luciferase plasmid (Promega Corp.), and agomiR-188 or agomiR-NC for 48 hours using Lipofectamine 2000 (Invitrogen). The dual luciferase reporter assay system (Promega Corp.) was used to quantify luminescent signal using a luminometer (Glomax; Promega Corp.). Each value from the firefly luciferase assay was normalized to the renilla luciferase value from the cotransfected phRL-null vector (Promega Corp.). The nucleotide sequences of primers for WT and mutant reporter plasmids are shown in Supplemental Table 2 .
Adipogenic differentiation assay. To induce adipogenic differentiation of BMSCs in vitro, BMSCs were cultured in 6-well plates at 2.5 × 10 6 cells per well with adipogenesis induction medium (α-MEM containing 10% FCS, 0.5 mM 3-isobutyl-1-methylxanthine, 5 μg/ml insulin, and 1 μM dexamethasone) for 14 days. Culture medium was changed every second day. We performed Oil Red O staining to detect mature adipocytes in cultures with adipogenesis induction.
Osteogenic differentiation and mineralization assay. To induce osteoblastic differentiation, BMSCs were cultured in 24-well plates at 5 × 10 5 cells per well with osteogenesis induction medium (300 ng/ml BMP-2, 50 μg/ml ascorbic acid, and 5 mM β-glycerolphosphate) for 48 hours. Then, the cell lysates were homogenized for ALP activity assay by spectrophotometric measurement of p-nitrophenol release using an enzymatic colorimetric ALP Kit (Roche). Culture media were collected for assessment of secreted osteocalcin levels using a specific immunoassay kit (DiaSorin).
To induce osteoblastic mineralization, BMSCs were cultured in 6-well plates at 2.5 × 10 6 cells per well with osteogenesis induction medium, as described above, for 21 days. Then, cells were stained with 2% Alizarin Red S (Sigma-Aldrich) at pH 4.2 to evaluate the cell matrix mineralization. A Diaphot Inverted Microscope and Camera System (Nikon) was used for imaging. Alizarin Red S released from the cell matrix into the cetyl-pyridinium chloride solution was quantified by spectrophotometry at 540 nm.
To normalize protein expression to total cellular protein, a fraction of the lysate solution was subjected to the Bradford assay.
Preosteoclast and osteoclast differentiation. Monocytes and macrophages were harvested from bone marrow of 6-month-old female WT and Mir188 -/mice by flushing of the femur and tibia marrow space. trabecular bones. To label the mineralization fronts, the mice were injected with 25 mg/kg calcein at 8 and 2 days before euthanasia. The femora were fixed in 70% ethanol and dehydrated in increasing concentrations of ethanol, and the undecalcified bones were embedded in methyl methacrylate. Serial 5-μm sections of the femur were made using a microtome. The parameters obtained for the bone formation were bone formation rate per bone surface, osteoblast surface per bone surface, and osteoblast number per bone perimeter. The parameters measured for bone resorption were osteoclast surface per bone surface and osteoclast number per bone perimeter.
Immunohistochemical staining. Immunohistochemical staining was performed as described previously (44, 45) . Briefly, bone sections were processed for antigen retrieval by digestion with 0.05% trypsin at 37°C for 15 minutes, and then incubated with primary antibody against osteocalcin (catalog M173; Takara) overnight at 4°C. Subsequently, an HRP-streptavidin detection system (Dako) was used to detect the immunoactivity, followed by counterstaining with hematoxylin (Sigma-Aldrich). Sections incubated with polyclonal rabbit IgG (R&D Systems Inc.) served as negative controls.
Identification of an aptamer using cell-SELEX procedure. The selection technology to generate aptamers is called systematic evolution of ligands by exponential enrichment (SELEX) (16) (17) (18) . The library of synthetic DNAs comprised a 40-base central random sequence flanked by primer sites on either side (5′-GAATTCAGTCGGA-CAGCG-N40-GATGGACGAATATCGTCTCCC-3′). Four-nanomole single-stranded DNA (ssDNA) pools were denatured by heating to 80°C for 10 minutes in a selection buffer containing 50 mM Tris-HCl (pH 7.4), 5 mM KCl, 100 mM NaCl, 1 mM MgCl 2 , and 0.1% NaN 3 and then renatured at 0°C for 10 minutes. The mouse BMSCs, monocytes/ macrophages, or preosteoclasts (10 6 cells for the first round and 10 5 cells for the further rounds) were incubated with the ssDNA at 37°C for 30 minutes in selection buffer. Partitioning of bound and unbound ssDNA sequences was done by centrifugation. After centrifugation and washing 3 times with 1 ml selection buffer (with 0.2% BSA), cellbound ssDNAs were amplified by PCR. Aptamers obtained from the tenth round of selection were PCR-amplified using unmodified primers and cloned into E. coli using the TA Cloning Kit (Promega Corp.). The plasmids of individual clones were isolated with a Plasmid Extraction Kit (QIAGEN), and the inserts were PCR-amplified and sequenced. The sequence of the aptamer that showed the highest binding affinity to mouse BMSCs was 5′-GAATTCAGTCGGACAGC-GACGACGGTGATATGTCAAGGTCGTATGCACGAGTCAGAGG-GATGGACGAATATCGTCTCCC-3′.
For flow cytometry analysis, cultured BMSCs, monocytes/macrophages, and preosteoclasts were washed with PBS and detached with nonenzymatic dissociation buffer for 15 minutes. After washing, the cells were incubated with a FITC-labeled ssDNA pool dissolved in 200 μl binding buffer at a final concentration of 250 nM for 45 minutes. Cells were washed twice with 1 ml washing buffer and resuspended in 200 μl binding buffer. Fluorescence was determined with a FACScan cytometer (BD Immunocytometry Systems).
Construction of BMSC-specific aptamer delivery system. The BMSCspecific aptamer was synthesized by Genscript Co. AgomiR-188, antagomiR-188, and their respective negative controls (NCs) were synthesized by RiboBio Co.
We mixed 1 part by volume of a polyethyleneimine (PEI) solution (100 μg/ml, pH 6.0) with 6 parts by volume of a 4.2-μM sodium citrate jci.org Volume 125 Number 4 April 2015
collected from the load-deformation curves. The maximum load (N) and stiffness (N/mm) were recorded. Study population. Human bone marrow samples were obtained from 48 patients (20 male and 28 female) with osteoarthritis undergoing knee joint replacement, with ages ranging from 54 to 82 years; 41 patients (27 male and 14 female) with femoral neck fracture and/or femoral head fractures undergoing hip joint replacement, with ages ranging from 50 to 89 years; and 54 patients (25 male and 29 female) with tibia fractures and 27 patients (13 male and 14 female) with femur shaft fracture undergoing open reduction internal fixation, ranging in age from 20 to 70 years (human bone marrow aspiration and collection were conducted by the Orthopedic Surgery Department at the Second Xiangya Hospital of Central South University). One hundred seventy patients (85 male and 85 female) were selected on the basis of the inclusion and exclusion criteria. All subjects were screened using a detailed questionnaire, disease history, and physical examination. Subjects were excluded from the study if they had had conditions affecting bone metabolism, including diseases of the kidney, liver, parathyroid, or thyroid, diabetes mellitus, hyperprolactinemia, oophorectomy, rheumatoid arthritis, ankylosing spondylitis, malabsorption syndromes, malignant tumors, hematological diseases, or previous pathological fractures, within the past year. If the subjects had received treatment with glucocorticoids, estrogens, thyroid hormone, parathyroid hormone, fluoride, bisphosphonate, calcitonin, thiazide diuretics, barbiturates, or antiseizure medication, they were also excluded. These participants underwent bone marrow aspiration and collection during bone fracture surgery and joint replacement.
Statistics. Data are presented as mean ± SD. For comparisons of 2 groups, 2-tailed Student's t test was used. Comparisons of multiple groups were made using 1-way ANOVA. All experiments were repeated at least 3 times, and representative experiments are shown. Differences were considered significant at P < 0.05.
Study approval. All animal care protocols and experiments were reviewed and approved by the Animal Care and Use Committee of the Laboratory Animal Research Center at Xiangya Medical School of Central South University. All mice were maintained in the specific pathogen-free facility of the Laboratory Animal Research Center at Central South University. The clinical study was approved by the Ethics Committee of the Second Xiangya Hospital of Central South University, and written informed consent was obtained from all participants prior to bone marrow aspiration and collection.
